BioRestorative Therapies (NASDAQ:BRTX) Posts Earnings Results, Beats Estimates By $0.22 EPS

BioRestorative Therapies (NASDAQ:BRTX) issued its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.22, Zacks reports. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 93.89%. The company had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.30 million.

BioRestorative Therapies Price Performance

Shares of NASDAQ:BRTX traded down $0.06 during trading on Thursday, hitting $1.48. 33,333 shares of the company were exchanged, compared to its average volume of 768,575. The stock has a market capitalization of $10.24 million, a P/E ratio of -1.00 and a beta of 63.40. BioRestorative Therapies has a 12-month low of $1.03 and a 12-month high of $3.67. The firm’s 50 day moving average price is $1.63 and its 200-day moving average price is $1.60.

Analysts Set New Price Targets

Separately, Roth Mkm lifted their price target on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.